Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

Carboplatin 7Pemetrexed 5pembrolizumab 4Gemcitabine 4osimertinib 3Sorafenib 3Paclitaxel 3Interleukin-2 3Cyclophosphamide 3Cisplatin 3seocalcitol 2selinexor 2patritumab 2liposomal doxorubicin 2interferon gamma-1b 2fludarabine 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Irinotecan 2Erlotinib Hydrochloride 2DNA 2Celecoxib 2Capecitabine 2Bleomycin 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2volociximab 1thioredoxin reductase inhibitor AM12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma × futuximab × Clear all
NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡